After Leerink Partners and KeyBanc gave Repligen (NASDAQ: RGEN) a Buy rating last month, the company received another Buy, this time from BNP Paribas. Analyst Hugo Solvet initiated coverage with a Buy rating on Repligen today and set a price target of $330.00. The company’s shares closed last Wednesday at $253.01.
Repligen has an analyst consensus of Strong Buy, with a price target consensus of $319.60.
Based on Repligen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $163 million and net profit of $36.23 million. In comparison, last year the company earned revenue of $87.46 million and had a net profit of $15.86 million.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.